Ignite Creation Date:
2024-05-05 @ 9:36 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00926107
Status:
TERMINATED
Last Update Posted:
2011-11-10
First Post:
2009-06-22
Brief Title:
Study of the mTOR Inhibitor Temsirolimus CCI-779 to Treat Ovarian Cancer With CA125 Only Relapse
Sponsor:
Hellenic Cooperative Oncology Group
Organization:
Hellenic Cooperative Oncology Group
Study Overview
Official Title:
Study of the mTOR Inhibitor TemsirolimusCCI-779 in Patients With CA125 Only Relapse of Ovarian Cancer A Phase II Study by the Hellenic Cooperative Oncology Group
Status:
TERMINATED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study ended prematurely due to the low accrual rate 24 of the expected accrual rate in the first two years of patients enrolment
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to determine the efficacy of Temsirolimus in patients with ovarian cancer with CA125 only relapse after first-line platinum-based chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2008-007925-38 | EUDRACT_NUMBER | None | None |